Interleukin-22 (IL-22)
Ultrasensitive Immunoassay
Rules-Based Medicine has developed an ultrasensitive immunoassay to interleukin-22 (IL-22) based on Simoa® bead technology. Being able to accurately quantitate sub-pg/mL levels of IL-22 in human serum and plasma is a valuable clinical research tool for pharmacodynamic analysis in oncology, autoimmune, and chronic inflammatory diseases.
IL-22, previously identified as an IL-10 related T cell derived inducible factor, is a member of the IL-10 superfamily, and its receptor is comprised of IL-22R1 and IL-10R2. Under homeostatic conditions, there is a soluble receptor, IL-22 binding protein (IL-22RA2), which prevents binding of IL-22 to the IL-22R1. While IL-22 is produced by mostly lymphocytes, such as T cell helper type 1 (TH1), TH17, TH22 cells, natural killer cells, gd T cells, and innate lymphoid cell group 3 (ILC3), the functional receptor is expressed on non-hematopoietic cells, mostly epithelial cells. Normal activity of IL-22 is to promote tissue repair and protect the barrier surface. As such, IL-22 plays important roles in several chronic diseases. In autoimmune diseases, such as Crohn’s, psoriasis, and atopic dermatitis high level of IL-22 in circulation is correlated with disease and/or disease severity. For patients with asthma, increased serum IL-22 is associated with disease and disease severity, and maybe a result of the host’s compensatory mechanism to control inflammation. While in cancer, especially for colorectal cancer, IL-22 promotes tumor development and growth, the hypothetical mechanism is most likely by inducing stem cell like characteristics. Circulating IL-22 has been correlated with both protective and pathogenic pathways in several disease states, and an ultrasensitive assay for IL-22 can aid in several phases of clinical research.
Swiss-Prot Accession Number: Q9GZX6
Alternate names for this biomarker include:
Cytokine Zcyto18, IL-10-related T-cell-derived-inducible factor, IL-TIF
| Biomarker | LLOQ* (Serum and Plasma) |
LLOQ* (Undiluted Samples) |
Volume Required | |
|---|---|---|---|---|
| Serum or plasma | Other fluids** | |||
| Interleukin-22 (IL-22) | 0.047 pg/mL | 0.01175 pg/mL | 100 µL | 150 µL |
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.